Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: PVX-410|BIOLOGICAL: Durvalumab|DRUG: Hiltonol
Sponsor: Massachusetts General Hospital
Collaborators: OncoPep, Inc.|AstraZeneca